You will be shown inclusion or exclusion criteria for a clinical trial. Given these criteria, your task is to extract all unique entities of the following types: ["Observation", "Condition", "Procedure", "Drug", "Temporal", "Multiplier", "Qualifier", "Negation", "ReferencePoint", "Scope", "Value", "Mood", "Device", "Visit", "Measurement", "Person"].

Please return the output as a JSON object of the format: {"Condition" : ["breast cancer", ...], "Device" : ["ports", ...], "Drug" : ["Atenolol", ...], "Measurement" : ["blood pressure", ...], "Mood" : ["suspected", ...], "Multiplier" : ["more than two", ...], "Negation" : ["no", ...], "Observation" : ["history", ...], "Person" : ["male", ...], "Procedure" : ["surgery", ...], "Qualifier" : ["severe", ...], "ReferencePoint" : ["enrollment", ...], "Scope" : ["infection", ...], "Temporal" : ["one day", ...], "Value" : ["50%", ...], "Visit" : ["ICU", ...]}. The keys should be entity types and values should be lists of extracted entities belonging to the corresponding type. If you cannot find entities belonging to a specific type, the value should be [].

Only output the JSON object and do not include any additional text.

Abstract:

Histological confirmation of relapsed/refractory diffuse large B-cell lymphoma after prior rituximab and anthracycline-containing systemic treatment regimen such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc. 
Subjects must have received no more than 2 prior systemic therapies for lymphoma. Prior therapy with systemic rituximab monotherapy or conventional chemotherapy (i.e. bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other) ± rituximab for indolent non-Hodgkin's lymphoma (NHL) ± maintenance/extended-use rituximab will count as 1 line of systemic therapy. 
Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2 
Subjects must have normal organ and marrow function as defined below: 
Hemoglobin ≥ 8.0 g/dl 
Absolute neutrophil count ≥ 1,000/mcL 
Platelet count ≥ 75,000/mcL 
Total bilirubin ≤ 1.5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert's, for whom the maximum will be 2.5 ULN. 
Aspartate transaminase (AST) (SGOT) ≤ 2.5 X institutional ULN 
Alanine transaminase (ALT) (SGPT) ≤ 2.5 X institutional ULN 
International normalized ratio (INR) > 1.5 ×ULN 
Patients must have a calculated serum creatinine clearance > 50 mL/min using Cockcroft-Gault calculation or based on 24-hour urine collection performed within 7 days prior to treatment. 
Specific guidelines will be followed regarding inclusion of relapsed/refractory DLBCL based on Hepatitis B serological testing as follow: 
HBsAg negative, HBcAb negative, HBsAb positive patients are eligible. 
Patients who test positive for HBsAg are ineligible 
Patients with HBsAg negative, but HBcAb positive (regardless of HBsAb status) should have a HBV DNA testing performed and protocol eligibility determined as follow: 
If HBV DNA is positive, the subject is ineligible. 
If HBV DNA is negative, the subject may be included but must undergo HBV DNA PCR testing monthly x 3 months beginning from the start of treatment 
Subjects must have the ability to understand and the willingness to sign a written informed consent document. 
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax or 18 months after the last dose of rituximab, whichever is longer. 
A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). 
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: 
With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab. Men must refrain from donating sperm during this same period. 
With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo.
{"Condition": ["impaired bilirubin conjugation", "B-cell lymphoma", "non-Hodgkin\u0027s lymphoma (NHL)", "normal organ function", "Gilbert\u0027s", "normal marrow function"], "Device": [], "Drug": ["rituximab", "etoposide phosphate", "doxorubicin hydrochloride", "bendamustine", "Cyclophosphamide", "R-EPOCH", "Vincristine Sulfate", "dexamethasone", "prednisone", "vincristine sulfate", "R-HyperCVAD", "vincristine", "CVP", "R-CHOP", "doxorubicin", "Prednisone", "cyclophosphamide", "anthracycline"], "Measurement": ["International normalized ratio (INR)", "Total bilirubin", "HBsAg", "Eastern Cooperative Oncology Group (ECOG) Performance status", "Alanine transaminase (ALT) (SGPT)", "HBsAb", "Aspartate transaminase (AST) (SGOT)", "HBV DNA", "Absolute neutrophil count", "HBcAb", "Hemoglobin", "Platelet count", "serum creatinine clearance"], "Mood": [], "Multiplier": ["no more than 2"], "Negation": [], "Observation": [], "Person": [], "Procedure": ["rituximab and anthracycline-containing systemic treatment regimen", "Histological", "HBV DNA testing", "conventional chemotherapy", "systemic therapies for lymphoma", "systemic monotherapy"], "Qualifier": ["24-hour urine collection", "maintenance", "extended-use", "diffuse", "large", "indolent", "Cockcroft-Gault calculation"], "ReferencePoint": ["treatment", "prior rituximab and anthracycline-containing systemic treatment regimen"], "Scope": ["\u2264 1.5 X the upper limit of normal (ULN) unless a known history of impaired bilirubin conjugation such as Gilbert\u0027s, for whom the maximum will be 2.5 ULN", "rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone", "R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), R-EPOCH (rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride), R-HyperCVAD (rituximab, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone) etc", "rituximab, etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride", "maintenance/extended-use", "Cyclophosphamide, Vincristine Sulfate, Prednisone", "bendamustine, CVP (Cyclophosphamide, Vincristine Sulfate, Prednisone) or other", "Subjects must have normal organ and marrow function as defined below:", "Cockcroft-Gault calculation or based on 24-hour urine collection", "rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone"], "Temporal": ["after", "prior", "within 7 days prior", "Prior"], "Value": ["\u2265 1,000/mcL", "maximum 2.5 ULN", "\u2264 2", "negative", "confirmation", "positive", "\u2265 75,000/mcL", "\u2264 2.5 X institutional ULN", "\u2264 1.5 X the upper limit of normal (ULN)", "\u2265 8.0 g/dl", "\u003e 1.5 \u00d7ULN", "\u003e 50 mL/min"], "Visit": []}